Patent: 5,093,246
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 5,093,246
Title: | RNA ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods |
Abstract: | RNA enzymes or ribozymes can act as endoribonucleases, catalyzing the cleavage of RNA molecules with a sequence specificity of cleavage greater than that of known ribonucleases and approaching that of the DNA restriction endonucleases, thus serving as RNA sequence specific endoribonucleases. An example is a shortened form of the self-splicing ribonsomal RNA intervening sequence of Tetrahymena (L-19 IVS RNA). Site-specific mutagenesis of the enzyme active site of the L-19 IVS RNA alters the substrate sequence specificity in a predictable manner, allowing a set of sequence-specific endoribonucleases to be synthesized. Varying conditions allow the ribozyme to act as a polymerase (nucleotidyltransferase), a dephosphorylase (acid phosphatase or phosphotransferase) or a sequence-specific endoribonuclease. |
Inventor(s): | Cech; Thomas R. (Boulder, CO), Zaug; Arthur J. (Louisville, CO), Been; Michael D. (Boulder, CO) |
Assignee: | University Patents, Inc. (Westport, CT) |
Application Number: | 07/562,672 |
Patent Claims: | see list of patent claims |
Details for Patent 5,093,246
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | See Plans and Pricing | 2009-03-03 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | See Plans and Pricing | 2009-03-03 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | See Plans and Pricing | 2009-03-03 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |